Physician profile
Aja Mccutchen
NPI 1578609780
$309,840.54
in general payments reported to CMS, 2019-2025
40 companies · $144K in 2025
The $144K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $3,224 · 2021: $9,002 · 2022: $34K · 2023: $41K · 2024: $78K · 2025: $144K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $142K · Consulting Fee: $73K · Honoraria: $22K · Travel and Lodging: $17K · Food and Beverage: $9,561 · Education: $39.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $141,822.66 |
| Consulting Fee | $72,945.25 |
| Honoraria | $22,001.32 |
| Travel and Lodging | $16,740.22 |
| Food and Beverage | $9,561.48 |
| Education | $39.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $60,179.42 | 2023-2025 | Omvoh, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $35,279.79 | 2019-2025 | Entyvio, Eohilia |
| E.R. Squibb & Sons, L.L.C. | $34,892.63 | 2021-2024 | Zeposia |
| Pfizer INC. | $33,210.10 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $32,543.94 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $30,596.15 | 2024-2025 | Zymfentra, Vegzelma |
| Genzyme Corporation | $27,897.12 | 2022-2025 | |
| Redhill Biopharma INC. | $16,963.53 | 2020-2022 | |
| Ardelyx, INC. | $13,274.36 | 2022-2025 | Ibsrela |
| Eli Lilly and Company | $9,338.66 | 2025 | Omvoh |
| Celgene Corporation | $4,694.56 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $3,731.05 | 2019-2025 | Stelara, Tremfya |
| Abbvie INC. | $2,894.18 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $1,316.31 | 2023-2025 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $804.62 | 2021-2025 | Xifaxan, Trulance, Plenvu |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $320.21 | 2023-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $241.43 | 2019-2025 | |
| Vivus LLC | $183.95 | 2021-2025 | Pancreaze, Qsymia |
| Intercept Pharmaceuticals, INC. | $176.58 | 2020-2023 | Ocaliva |
| Medtronic, INC. | $161.11 | 2024 | Interstim |
| Aimmune Therapeutics, INC. | $160.15 | 2023-2025 | Zenpep |
| Boston Scientific Corporation | $115.83 | 2022-2025 | Axonics, Watchman Flx |
| Janssen Scientific Affairs, LLC | $115.12 | 2025 | Tremfya |
| Merck Sharp & Dohme LLC | $99.19 | 2019-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $88.57 | 2025 | Iqirvo |
| Organon LLC | $85.07 | 2021-2025 | Renflexis, Hadlima |
| Madrigal Pharmaceuticals | $68.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $58.48 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $57.84 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $55.79 | 2021-2022 | |
| Exact Sciences Corporation | $49.98 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.79 | 2023 | |
| Braintree Laboratories, INC. | $27.55 | 2021-2024 | Sutab, Suflave |
| Amgen INC. | $25.18 | 2023 | Amjevita, Avsola |
| Allergan, INC. | $21.27 | 2019 | |
| Novo Nordisk INC | $19.40 | 2025 | Wegovy |
| Shionogi INC | $19.04 | 2019 | |
| Ferring Pharmaceuticals INC. | $17.37 | 2021 | |
| Alfasigma USA, INC. | $14.64 | 2020 | |
| Evoke Pharma, INC. | $14.19 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aja Mccutchen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.